$ECOR I SEE DIS electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
income statement | balance sheet | cash flow annual | quarterly
Period End Date TTM 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Period Length 12 Months 12 Months 12 Months 12 Months 12 Months
Total Revenue
3.24 2.39 0.99
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.
Learn more
Cost of Revenue
1.31 1.16 0.58
Gross Profit
1.93 1.23 0.41
Selling, General and Administrative
23.69 35.42 42.50
Research and Development
4.81 9.90 12.47
Unusual Expense/Income
0.46 2.00 0.00
Total Operating Expense
30.27 48.48 55.55
Operating Income
-27.03 -46.09 -54.55
Interest Income Net
0.20 0.97 1.01
Other Income Net
-0.01 -0.01 -2.22
Net Income Before Taxes
-26.84 -45.13 -55.76
Provision for Income Taxes
-1.15 0.02 0.00
Net Income
-25.69 -45.15 -55.82
Income Avail. to Common Excl. Extraord.
-25.69 -45.15 -55.82
Income Avail. to Common Incl. Extraord.
-25.69 -45.15 -55.82
Diluted Average Shares
34.99 29.38 29.26
Diluted EPS Excl. Extraord.
-0.78660 -1.53669 -1.90761
Diluted EPS Incl. Extraord.
-0.78660 -1.53669 -1.90761
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
income statement | balance sheet | cash flow annual | quarterly
Period End Date TTM 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Period Length 12 Months 12 Months 12 Months 12 Months 12 Months
Total Revenue
3.24 2.39 0.99
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.
Learn more
Cost of Revenue
1.31 1.16 0.58
Gross Profit
1.93 1.23 0.41
Selling, General and Administrative
23.69 35.42 42.50
Research and Development
4.81 9.90 12.47
Unusual Expense/Income
0.46 2.00 0.00
Total Operating Expense
30.27 48.48 55.55
Operating Income
-27.03 -46.09 -54.55
Interest Income Net
0.20 0.97 1.01
Other Income Net
-0.01 -0.01 -2.22
Net Income Before Taxes
-26.84 -45.13 -55.76
Provision for Income Taxes
-1.15 0.02 0.00
Net Income
-25.69 -45.15 -55.82
Income Avail. to Common Excl. Extraord.
-25.69 -45.15 -55.82
Income Avail. to Common Incl. Extraord.
-25.69 -45.15 -55.82
Diluted Average Shares
34.99 29.38 29.26
Diluted EPS Excl. Extraord.
-0.78660 -1.53669 -1.90761
Diluted EPS Incl. Extraord.
-0.78660 -1.53669 -1.90761
Recent ECOR News
- electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation • GlobeNewswire Inc. • 04/23/2026 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/15/2026 08:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:05:06 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:01:02 PM
- electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 08:01:05 PM
- electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD • GlobeNewswire Inc. • 04/01/2026 12:00:00 PM
- electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:50 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/19/2026 09:22:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2026 08:35:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:10:30 PM
- electroCore Announces Full Year 2025 Financial Results and Organizational Changes • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- electroCore to Participate at the 38th Annual Roth Conference • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026 • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 09:30:06 PM
- Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) • GlobeNewswire Inc. • 01/21/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:52 PM
- electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million • GlobeNewswire Inc. • 01/20/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:15:45 PM
- TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen • GlobeNewswire Inc. • 12/02/2025 01:00:00 PM
- electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum • GlobeNewswire Inc. • 11/10/2025 09:05:00 PM
